Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 16,007 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, 400 to 500 calorie, Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, bedtime, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Conditions
Non Small Cell Lung Cancer
Interventions
Ramucirumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 4 more
Terminated Phase 2 Interventional Results available

Nivolumab Combined With BMS-986253 in HCC Patients

NCT04050462
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks, Nivolumab 240 mg IV every 2 weeks
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Single Low-Dose of Supplement Amino Acid

NCT01540773
Conditions
Growth Hormone, Amino Acid
Interventions
Amino acid supplement, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Cancer
Interventions
panitumumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Primary Sclerosing Cholangitis
Interventions
Oral Vancomycin
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Advanced Solid Tumors
Interventions
interferon-gamma and nivolumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer
Interventions
low intensity radiation therapy, Capecitabine, Gemcitabine, high intensity radiation therapy, nab-Paclitaxel
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
46
States / cities
Oakland, California • Santa Clara, California • South San Francisco, California + 39 more
Completed Not applicable Interventional Accepts healthy volunteers

Interaction of Salivary Proteins and Polyphenols

NCT03501238
Conditions
Diet Habit, Diet Modification, Taste, Altered, Saliva Altered
Interventions
Chocolate Milk, Chocolate milk substitute, Chocolate milk substitute with gelatin
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
West Lafayette, Indiana
Conditions
Prostate Cancer
Interventions
ARN-509, LHRH Agonist
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
Conditions
Prostate Cancer
Interventions
ABX-EGF
Drug
Lead sponsor
Abgenix
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 6 more
Conditions
Pregnancy, High Risk, Type 1 Diabetes, Type 2 Diabetes
Interventions
Insulin, DEXCOM Continuous Glucose Monitor
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Neoplasms, Diarrhea
Interventions
Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Burbank, California • Concord, California • Fountain Valley, California + 31 more
Conditions
Polycystic Ovary Syndrome
Interventions
Nutropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, autologous stem cell transplantation, stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease

NCT01427517
Conditions
Parkinson's Disease, Gaucher's Disease
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 2 Interventional Results available

Islet Transplantation Using Abatacept

NCT00276250
Conditions
Type 1 Diabetes Mellitus
Interventions
Efalizumab, Abatacept, Belatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass
Interventions
Antithrombin III
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 1 Year
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
AADC Deficiency
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
24 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
3
States / cities
San Francisco, California • Columbus, Ohio
Conditions
Lymphoma
Interventions
KGEL vaccine, Filgrastim, Rituximab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Metastatic Breast Cancer
Interventions
carboplatin, bevacizumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Park Ridge, Illinois